Octave Bioscience, a Menlo Park, CA-based precision care company for managing multiple sclerosis and other neurodegenerative diseases, received a $10M Grant from The Michael J. Fox Foundation.
The grant will be used for discovery, development, and validation of a custom protein biomarker panel to measure parkinson’s disease activity and progression in the clinic.
Led by William Hagstrom, Octave Bioscience is a commercial stage precision-medicine company delivering care for multiple sclerosis and other neurodegenerative diseases. Its precision care solution is a measurement tool that measures disease activity, progression, and severity, allowing for better management of complex neurodegenerative diseases, starting with multiple sclerosis and expanding into parkinson’s disease. The Octave Solution includes the Octave MSDA Test, a multivariate blood test for multiple sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers.
Octave Bioscience is currently collaborating with clinics, payers, and pharma companies across the country. The company’s Precision Care Solution is currently in use in over 50 clinics across the United States.
FinSMEs
16/11/2023